Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare's new initiative to ease access to GLP-1 medications by capping monthly payments at $50 is promising but has a significant limitation: not all eligible seniors will qualify for this discount, especially those with the most severe health conditions. This means while some patients will benefit from lower out-of-pocket costs, others might still face high expenses, raising questions about the program's effectiveness in truly aiding vulnerable populations. The implications could be significant, as it highlights the ongoing challenges in ensuring equitable access to essential medications for all Medicare beneficiaries.